Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis, Zurich University Spin-out Anaveon Tackles IL-2 Challenges With Fresh Funds

Executive Summary

Syncona and Novartis Venture Fund have invested CHF35m in Anaveon, which reckons it can overcome the toxicity and half-life limitations of the cytokine interleukin-2 to enhance the body’s immune response to tumors.

You may also be interested in...



Anaveon To Take A Different Clinical Path With Novel IL-2 Therapy

Anaveon of Switzerland plans to take the clinical road less travelled with its novel interleukin-2 agonist, ANV419, its CEO told Scrip as the firm launched a Phase I/II study for its lead asset.

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Synthorx Throws THOR-707 Into Competitive IL-2 Space With HAMMER, Its First-Ever Clinical Trial

Emerging Company Profile: This is the first human study for lead product candidate THOR-707 and for the company's Expanded Genetic Alphabet platform, starting with a recombinant IL-2 that's being tested in solid tumors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel